Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194774 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Trends in Medicare Coverage of Overactive Bladder Medications in the United States.
Urogynecology (Phila)
December 2024
From the Urogynecology and Reconstructive Pelvic Surgery, MedStar Washington Hospital Center/Georgetown University, Washington, DC.
Importance: Strong evidence demonstrates long-term cognitive decline associated with anticholinergics. While prevalent among older populations, medical management of overactive bladder (OAB) is dictated by insurance coverage rather than medical provider and patient preferences.
Objective: The aim of this study was to assess Medicare insurance plan coverage for select OAB medications and evaluate coverage of preferred medications to medications with a greater risk of cognitive dysfunction.
Biomarkers.
Alzheimers Dement
December 2024
Roche Diagnostics International AG, Rotkreuz, Zug, Switzerland.
Background: Use of neuroimaging [e.g. magnetic resonance imaging (MRI), positron emission tomography (PET), or computed tomography (CT) scan], cerebrospinal fluid (CSF), and blood biomarker tests can contribute to a more accurate and earlier diagnosis of Alzheimer's disease (AD).
View Article and Find Full Text PDFBackground: With the rapid aging of the US population, the prevalence of dementia is projected to double. The enactment of the Affordable Care Act and Medicaid expansion could create opportunities for detection and classification of dementia. There are trends of increasing dementia mortality, however, it is unknown whether Medicaid expansion increased the reporting of dementia as the underlying cause of death (UCOD) or as a multiple cause of death (MCOD) among the elderly.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Background: Fatigue is prevalent in later life and may increase dementia risk independent of health conditions. Yet, existing epidemiologic studies include samples that are not nationally representative of U.S.
View Article and Find Full Text PDFBackground: Medical comorbidity burden has a substantial impact on care for patients with dementia and has major impacts on quality of life. No nationwide study has evaluated trends in medical comorbidity burden of patients with a new diagnosis of dementia. We therefore performed a nationwide study of medical claims data to understand the prevalence of comorbid medical conditions at time of dementia diagnosis in real-world clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!